Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.
The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept after once-weekly subcutaneous administrations of amycretin in 125 people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks.
The primary endpoint was treatment emergent adverse events. The safety profile of amycretin was consistent with incretin-based therapies. The most common adverse events with amycretin were gastrointestinal and the vast majority were mild to moderate in severity.
When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks). People treated with placebo experienced an estimated 1.9%, 2.3% and 2.0% body weight gain, respectively.
“We are very encouraged by the subcutaneous phase 1b/2a results for amycretin in people living with overweight or obesity,” said Martin Lange, executive vice president for Development at Novo Nordisk. “The results seen in the trial support the weight lowering potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, that we have previously seen with the oral formulation.”
Based on the results, Novo Nordisk is now planning further clinical development of amycretin in adults with overweight or obesity.
About amycretin
Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is developed for oral and subcutaneous administration.
About the Phase 1b/2a subcutaneous amycretin trial
The trial was a randomised, placebo-controlled and double-blinded study assessing the safety, tolerability, pharmacokinetics, and proof-of-concept after subcutaneous administration of amycretin in people with overweight or obesity. The trial was conducted in 5 parts: A single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B). Lastly, in the proof-of-concept part, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).
Novo Nordisk, a leading global healthcare company, has announced the successful completion of a phase 1b/2a trial with their innovative subcutaneous amycretin treatment in individuals with overweight or obesity.
Amycretin is a novel compound that targets key mechanisms involved in weight regulation, offering a promising new approach to tackling the growing global epidemic of obesity. The trial results have shown encouraging efficacy and safety profiles, paving the way for further development of this potential game-changing therapy.
The successful completion of this trial marks an important milestone for Novo Nordisk in their mission to provide innovative solutions for individuals struggling with overweight or obesity. With obesity rates on the rise worldwide, the need for effective and safe treatments has never been more urgent.
Novo Nordisk remains committed to advancing research and development in the field of obesity management, and looks forward to bringing amycretin one step closer to becoming a reality for patients in need. Stay tuned for more updates on this exciting development in the fight against obesity.
Tags:
- Novo Nordisk
- Phase 1b/2a trial
- Subcutaneous amycretin
- Overweight
- Obesity
- Clinical trial
- Weight management
- Medical research
- Novo Nordisk trial results
- Amycretin treatment
#Novo #Nordisk #successfully #completes #phase #1b2a #trial #subcutaneous #amycretin #people #overweight #obesity